NCT06087874 is a Phase 2 clinical trial of Vivomixx® in Neonatal Jaundice, sponsored by Chinese University of Hong Kong.

Who is sponsoring NCT06087874?

NCT06087874 is sponsored by Chinese University of Hong Kong.

What drugs are being tested in NCT06087874?

Interventions in NCT06087874: Vivomixx®, Placebo.

What condition does NCT06087874 study?

NCT06087874 studies Neonatal Jaundice, Microtia, Pregnancy Related, Hyperbilirubinemia, Neonatal.

Is NCT06087874 still recruiting?

NCT06087874 is currently status unknown. Last updated 17 May 2024.

Last reviewed 2024-05-17 · How we verify

NCT06087874

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preventive Effect of Perinatal Oral Probiotic Supplementation (POPS) on Neonatal Jaundice: A Randomized Double-Blind Placebo-Controlled Parallel-Group Superiority Clinical Trial

Status unknown Phase 2 Last updated 17 May 2024

What this trial tests

Phase 2 trial testing Vivomixx® in Neonatal Jaundice in 94 participants. Status unknown.

Timeline

23 March 2024

Primary endpoint
1 February 2025

1 June 2025

Quick facts

Lead sponsor	Chinese University of Hong Kong
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	94
Start date	23 March 2024
Primary completion	1 February 2025
Estimated completion	1 June 2025
Sites	1 location across Hong Kong

Drugs / interventions tested

Vivomixx®
Placebo

Conditions studied

Neonatal Jaundice — all drugs for Neonatal Jaundice →
Microtia — all drugs for Microtia →
Pregnancy Related — all drugs for Pregnancy Related →
Hyperbilirubinemia, Neonatal — all drugs for Hyperbilirubinemia, Neonatal →

Sponsor

Chinese University of Hong Kong

Who can join

Adults 18 to 45, female only, with Neonatal Jaundice or Microtia. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Hyperbilirubinemia
Time frame: 1 week since birth
Investigators will measure the transcutaneous bilirubin level on the second and seventh day of life and plot the record on the nomograph. The record above the 95th percentile will be taken as considerable hyperbilirubinemia and then the baby will be investigated for total serum bilirubin measurement if needed to declare hyperbilirubinemia. The outcome will be classified as hyperbilirubinemia and n
Transcutaneous bilirubin level
Time frame: 1 week of life (after birth)
Infant's skin bilirubin level on the chest measured using a non-invasive devise called Drager meter. It will be measured in milligram per decilitre or micromole per liter. This outcome will be measured as a continuous outcome.

Sponsor's own description

This is a randomized double-blind placebo-controlled parallel group superiority clinical trial among 94 pregnant women (47 in each group) to investigate the effect of maternal perinatal probiotic supplementation on neonatal jaundice, breast milk microbiome, maternal stool, and infant fecal microbiome. Vivomixx®-probiotic product will be used as treatment and placebo as a control.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Preventive effect of prenatal maternal oral probiotic supplementation on neonatal jaundice (POPS Study): A protocol for the randomised double-blind placebo-controlled clinical trial.
Alemu BK, Lee MW, Leung MBW, Lee WF, et al · · 2024 · cited 5× · PMID 38851232 · DOI 10.1136/bmjopen-2023-083641

Verify or expand the search:

Other trials of Vivomixx®

Trials testing the same drug.

NCT03906578 — Effects of a Probiotic in Hypertension · NA · active not recruiting
NCT02957591 — Probiotic Supplementation in Severe Depression · NA · completed

Other recruiting trials for Neonatal Jaundice

Currently open trials in the same condition.

NCT06963450 — NeoSCB App for Screening Jaundice in Newborns · recruiting
NCT06399146 — Evaluation of Bilirubin Estimates in Newborns From Smartphone Digital Images in a Population in Botswana · NA · recruiting
NCT05521607 — Evaluation of a Smartphone-based Screening Tool (Picterus JP) for Neonatal Jaundice (Chicago) · NA · recruiting

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06087874 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 17 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06087874.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing